Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of “Buy” by Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX) has earned an average recommendation of “Buy” from the six analysts that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $9.50.

QNCX has been the topic of several research reports. Brookline Capital Management began coverage on shares of Quince Therapeutics in a report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price objective on the stock. D. Boral Capital restated a “buy” rating and issued a $12.00 target price on shares of Quince Therapeutics in a report on Wednesday, February 5th.

Quince Therapeutics Price Performance

Shares of NASDAQ:QNCX opened at $1.38 on Tuesday. The stock’s 50 day moving average is $1.54 and its 200-day moving average is $1.42. Quince Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.45. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $60.72 million, a price-to-earnings ratio of -1.11 and a beta of 0.71.

Hedge Funds Weigh In On Quince Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Quince Therapeutics by 24.2% during the third quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock valued at $263,000 after purchasing an additional 66,170 shares in the last quarter. Anfield Capital Management LLC purchased a new stake in Quince Therapeutics in the 4th quarter valued at about $50,000. Scharf Investments LLC bought a new position in shares of Quince Therapeutics during the 4th quarter worth approximately $170,000. Two Sigma Investments LP purchased a new position in shares of Quince Therapeutics in the 4th quarter worth approximately $57,000. Finally, Northern Trust Corp grew its holdings in shares of Quince Therapeutics by 48.5% in the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after acquiring an additional 16,501 shares in the last quarter. 30.75% of the stock is owned by hedge funds and other institutional investors.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.